An ongoing phase III study [236] (LIBImAb; NCT04776655) aims to assess the superiority of bevacizumab compared to cetuximab with FOLFIRI in mCRC which exhibit RAS/BRAF wt status on tumor tissue, but appear mutated in plasma analysis. The gene discussed is BRAF; the disease is neoplasm.